FRM
TVRD

Fox Run Management’s Tvardi Therapeutics TVRD Stock Holding History

Fox Run Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-384
Closed -$148K – 971
2022
Q4 		$148K Buy
+384
New +$146K 0.06% 525
2022
Q2 		– Sell
-304
Closed -$133K – 780
2022
Q1 		$133K Buy
+304
New +$125K 0.07% 446
2018
Q1 		– Sell
-356
Closed -$157K – 965
2017
Q4 		$157K Buy
+356
New +$162K 0.05% 608

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's TVRD Position: Q1 2023 in Review

Fox Run Management sold out of Tvardi Therapeutics (TVRD) in Q1 2023, closing a stake of 384 shares — an estimated $148K sold.

Fox Run Management first reported a position in TVRD in Q4 2017 and held it in 3 quarters. The position peaked at $157K in Q4 2017. 162 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Fox Run Management reported no remaining Tvardi Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Fox Run Management sold 384 Tvardi Therapeutics shares in Q1 2023, an estimated $148K.
  • Fox Run Management first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 3 quarters.
  • Fox Run Management's Tvardi Therapeutics position peaked at $157K in Q4 2017.
  • 162 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.